Ontology highlight
ABSTRACT: Objective
We conducted an open-label, phase I study using autologous umbilical cord blood (UCB) infusion to ameliorate type 1 diabetes (T1D). Having previously reported on the first 15 patients reaching 1 year of follow-up, herein we report on the complete cohort after 2 years of follow-up.Research design and methods
A total of 24 T1D patients (median age 5.1 years) received a single intravenous infusion of autologous UCB cells and underwent metabolic and immunologic assessments.Results
No infusion-related adverse events were observed. β-Cell function declined after UCB infusion. Area under the curve C-peptide was 24.3% of baseline 1 year postinfusion (P < 0.001) and 2% of baseline 2 years after infusion (P < 0.001). Flow cytometry revealed increased regulatory T cells (Tregs) (P = 0.04) and naive Tregs (P = 0.001) 6 and 9 months after infusion, respectively.Conclusions
Autologous UCB infusion in children with T1D is safe and induces changes in Treg frequency but fails to preserve C-peptide.
SUBMITTER: Haller MJ
PROVIDER: S-EPMC3220832 | biostudies-literature | 2011 Dec
REPOSITORIES: biostudies-literature
Haller Michael J MJ Wasserfall Clive H CH Hulme Maigan A MA Cintron Miriam M Brusko Todd M TM McGrail Kieran M KM Sumrall Theresa M TM Wingard John R JR Theriaque Douglas W DW Shuster Jonathan J JJ Atkinson Mark A MA Schatz Desmond A DA
Diabetes care 20111019 12
<h4>Objective</h4>We conducted an open-label, phase I study using autologous umbilical cord blood (UCB) infusion to ameliorate type 1 diabetes (T1D). Having previously reported on the first 15 patients reaching 1 year of follow-up, herein we report on the complete cohort after 2 years of follow-up.<h4>Research design and methods</h4>A total of 24 T1D patients (median age 5.1 years) received a single intravenous infusion of autologous UCB cells and underwent metabolic and immunologic assessments. ...[more]